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Introduction: Cancer clinical trials frequently incorporate quality
of life (QoL) measures but rarely patient utility. Utility information
is required for cost utility evaluations of novel cancer therapies. We
assessed the feasibility of converting QoL data into utility scores
using the European Organization for Research and Treatment of
Cancer Quality of Life-Core 30 questionnaire (EORTC QLQ-C30)
and the EQ-5D in patients with non-small cell lung cancer
(NSCLC).
Methods: Outpatients with all different disease states of NSCLC
attending a major Canadian cancer center completed the QLQ-C30
and EQ5D on a single visit. Results of the QLQ-C30 summary
scores were mapped to predict EQ-5D utility scores using linear
regression. Backward variable elimination using the Akaike Infor-
mation Criterion was used to reduce the full model that included all
QLQ-C30 summary scores to examine which QLQ-C30 dimensions
best predict a patient’s utility score. To test the predictive power of
the model, 10-fold cross-validation was used.
Results: A total of 172 patients participated in the study. Median
age of the sample was 66 years (range, 32–85 years); 46.5% were
men. The cross-validation estimate of mean utility score was 0.76
(SD: 0.20), which was the same as the actual mean utility score. Of
the 15 QLQ-C30 dimensions, 4 functional dimensions (physical,
role, emotional, and social) and the pain symptom dimension were
predictive of patient utility scores.
Conclusions: Our study demonstrates the feasibility of deriving
utility scores from prospective QoL data. Validation of the QLQ-
C30 predictors found in this study could further the ability to
estimate cost utility of therapies for economic evaluations.
Key Words: Non-small cell lung cancer, EQ-5D, EORTC QLQ-
C30, Derivation of utility values, Economic evaluation.
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Cancer clinical trials frequently measure quality of life(QoL) using multidimensional QoL instruments, such as
the European Organization for Research and Treatment of
Cancer Quality of Life Core 30 questionnaire (EORTC QLQ-
C30)1 and the Functional Assessment of Cancer Therapy-
General (FACT-G) questionnaire.2 The questionnaires yield
multiple values corresponding to different dimensions of
patients’ QoL; however, in economic analyses such as cost-
utility analyses, a single universal measure of health outcome,
such as a utility measure, is needed to compare different
therapies.3 In other words, utility measures differ from QoL
measures in that they combine the positive and negative
aspects of a health state into a single number and thereby
provide a common unit of analysis when comparing different
types of treatment.3 Patient utility is commonly used as a
measure of preference, anchored at 0 (death) and 1 (perfect
health).4 Despite the preference for utility measurements,
most clinical trials do not collect data routinely on patient
utility, in part because of time constraints, costs, and lack of
interest from sponsors and investigators.
When utility values are required for economic evalua-
tions of novel therapies but have not been collected as part of
clinical trials, there is a need to consider alternative ap-
proaches. Alternate approaches to the prospective collection
of utilities include the use of a global QoL question incorpo-
rated in some QoL instruments or the use of linear scoring
rules wherein subscales of different dimensions are summed
to produce a comprehensive score. However, none of these
approaches produces a true utility value that corresponds to
an established decision science framework, because true
utility scores should be based on preferences for different
health states.4 Furthermore, linear scoring rules may be mis-
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leading because of nonlinearity in preferences for different
outcomes.5 For these reasons, cost utility evaluations of novel
cancer therapies remain a challenge. A third alternative,
where utility data have not been collected prospectively in a
trial, is to use statistical models to convert prospectively
collected QoL data into utility scores. Mortimer has reviewed
these models, some of which have been developed for pa-
tients with cancer.6,7 Our study used this third alternative
approach and explored the association between QoL data
obtained with two commonly used instruments, the EORTC
QLQ-C30 and the EQ-5D, from patients with non-small cell
lung cancer (NSCLC).
METHODS
A total of 172 consecutive outpatients with NSCLC
attending a major Canadian cancer center outpatient clinic
were invited to complete the EORTC QLQ-C30 and EQ-5D
at a single visit. Demographic information including age,
disease stage, and disease state were extracted from patient
charts. Disease states included (1) relapse-free post-resection,
including on adjuvant chemotherapy; (2) in relapse but on no
treatment or receiving palliative chemotherapy or targeted
therapy (erlotinib); and (3) receiving radical chemoradiation
for locally advanced (stage III) NSCLC.
The EORTC QLQ-C30 is a self-administered, cancer-
specific questionnaire that has multidimensional scales con-
sisting of five functional domains (physical, role, emotional,
cognitive, and social); three symptom domains (fatigue, nau-
sea/vomiting, and pain); six single-item symptom scores
(dyspnea, sleep, appetite, constipation, diarrhea, and financial
impact), and a global health/QoL domain (overall health and
overall QoL in the past week).1 Responses are scored on a
scale from 1 (not at all) to 4 (very much), with the exception
of questions related to the global QoL domain scale, which
are scored on a scale from 1 (very poor) to 7 (excellent). For
our analysis, the 30 questions of the QLQ-C30 were col-
lapsed into 15 dimensions listed above as per the EORTC
QLQ-C30 scoring manual.8 QLQ-C30 scores for these vari-
ables were obtained by first calculating the raw score (RS),
where RS (I1… In)/n, where I1 to In are the responses
to questions included in the variable. Then a linear transfor-
mation was applied to scale the scores between 0 and 100.
For functional and symptom scores, the new score  (1 
[{RS  1}/n])  100, and for the global QoL score, the new
score  ([RS  1]/n)  100. Thus, a high score for a
functional or global dimension represents a high level of
functioning, but a high score for a symptom dimension
represents a high level of symptomatology. Finally, the QLQ-
C30 does not provide a direct or indirect measure of utility.
The EQ-5D is a generic health-related QoL instrument
that consists of five dimensions: mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression.9,10 Be-
cause each dimension has three possible levels, 243 (35)
unique health states exist. It also includes a visual analog
scale for self-assessment of current general health. The
EQ-5D provides an indirect measure of utility scores, because
valuation studies with different populations have been done
where each possible health state in EQ-5D has been assigned
a utility score using validated methods such as the time
trade-off method. The end result of these valuation studies is
a schedule of utility scores or tariffs corresponding to differ-
ent health states for a specific population, usually a country.
For our study, the US population tariffs were used.11
Results of the QLQ-C30 were mapped to predict
EQ-5D utility scores using a linear regression model. Utility
scores obtained from the EQ-5D were regressed on the 15
QLQ-C30 dimensions. Backward variable elimination12 us-
ing the Akaike Information Criterion (AIC) was used to
reduce the full model to examine which QLQ-C30 dimen-
sions best predict a patient’s utility score. AIC was used to
account for the tradeoff between complexity and fit of the
model. Coefficients for the linear regression model were
calculated for the full model and the reduced model. Interac-
tions between variables were not investigated.
To test the predictive performance, 10-fold cross-vali-
dation was used. In 10-fold cross-validation, the sample is
partitioned into 10 approximately equal subsets. Models were
fit using nine of the subsets, and the remaining subset is used to
validate the fitted model. The process was completed 10 times,
such that each subset was used as the validation sample exactly
once. Mean squared error was calculated to measure deviation of
the predicted from the actual utility value. Predicted and actual
utility scores were also compared by disease state and stage. A
3000-replicate bootstrap was used to derive 95% confidence
intervals (CIs). All analyses were performed using the R lan-
guage for statistical computing, version 2.8.
The protocol was approved by the research ethics board
at the Princess Margaret Hospital, Toronto, Canada, and all
patients provided written informed consent to participate.
RESULTS
The characteristics of participants are listed in Table 1.
All four stages of NSCLC were represented, although the
TABLE 1. Characteristics of Participants (n  172)
Age (yr)
Median 66
Range 32–85
Male sex (%) 80 (46.5)
Disease stage (%)
Stage I 34 (19.8)
Stage II 16 (9.3)
Stage III 36 (20.9)
Stage IV 86 (50)
Clinical state
Relapse free
On chemotherapy 9
Postchemotherapy 27
No chemotherapy 34
In relapse
On chemotherapy 24
On erlotinib 31
No current treatment 33
Locally advanced
On chemoradiation 14
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majority had stage IV. Table 2 lists mean EORTC QLQ-C30
scores by functional and symptom scales.
The final linear model after stepwise variable reduction
based on AIC included four functioning scales (physical, role,
emotional, and social) and one symptom scale (pain). Phys-
ical functioning and pain had the largest absolute coefficient
values, with values of 0.0039 and 0.0021, respectively, in
the reduced model. Other coefficients for the original full
model and reduced models are presented in Table 3. Adjusted
R2 values for the linear models were 0.57 and 0.58 for the full
and reduced linear models, respectively.
The mean square error using 10-fold cross-validation
was 0.02. Figure 1 shows the distribution of the estimated
errors (actual minus predicted utility scores), whereas Figure
2 shows scatter plots with actual and predicted utility scores.
Mean predicted utility score based on the cross-valida-
tion was 0.76, which was the same as actual mean utility
score. Subgroup analysis was performed by disease stage and
disease state (Table 4), as well as the mean and 95% boot-
strap CIs for the difference between the actual and predicted
scores. The 95% bootstrap CI did not include 0, hence
representing poor prediction for the subgroup in relapse and
on erlotinib.
DISCUSSION
With the escalating cost of novel cancer therapies,
cost-utility analyses have become increasingly more impor-
tant. Currently, many clinical trials do not collect utility
values but do collect QoL data through instruments such as
the QLQ-C30 and FACT-G. Hence, there has been growing
interest in models that reliably convert QoL data into utility
scores. We studied the application of a linear regression
model in patients with NSCLC to convert from the EORTC
QLQ-C30 data to utility scores derived via the EQ-5D.
The linear regression model performed well and repre-
sents a promising approach of converting QoL data into
utility scores. Of the 15 QLQ-C30 dimensions, 4 function
dimensions (physical, role, emotional, and social) and the
pain dimension were most predictive of utility score, as
evidenced by their inclusion in the reduced model. Of these
dimensions, physical function and pain had the most weight
in the calculation of the utility score. The QLQ-C30 dimen-
sions in the reduced model have significant overlap with the
EQ-5D dimensions (e.g., the physical QLQ-C30 dimension
corresponds to the mobility EQ-5D dimension and the emo-
tional QLQ-C30 dimension corresponds to the anxiety/de-
pression EQ-5D dimension), which is likely the reason why
the dimensions in the reduced model best predict EQ-5D
utility scores. However, by the same token, the QLQ-C30
dimensions in the reduced model cannot be considered to be
the only important factors contributing to a patient’s utility
score, because there may be other dimensions such as a
patient’s financial difficulties that are not captured in the
EQ-5D model.
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FIGURE 1. Histogram of the estimated errors (actual minus
predicted utility scores).
TABLE 2. Mean EQ-5D Scores and QLQ-C30 Scores
Mean  SD 95% Bootstrap CI
EQ-5D
Utility score 0.76  0.20 0.73–0.78
VAS 67.22  19.77 64.17–70.19
QLQ-C30
Physical functioning 73.25  21.81 70.08–76.54
Role functioning 67.44  31.62 62.60–72.09
Emotional functioning 75.19  24.05 71.51–78.68
Cognitive functioning 79.84  22.67 76.36–83.14
Social functioning 73.16  29.20 68.70–77.33
Global health status/QoL 65.89  20.44 62.79–68.94
Fatigue 40.83  25.94 37.02–44.70
Nausea and vomiting 7.56  15.22 5.43–9.98
Pain 25.68  28.80 21.51–29.84
Dyspnea 31.20  30.19 26.74–36.05
Insomnia 34.88  33.97 29.84–40.12
Appetite loss 22.67  30.74 18.22–27.33
Constipation 18.99  28.86 14.92–23.26
Diarrhea 13.37  24.36 9.88–17.25
Financial difficulties 23.06  33.30 18.41–28.10
VAS, visual analog scale; CI, confidence interval; QoL, quality of life.
TABLE 3. Coefficients for the Linear Regression Model
Full Model Reduced Model
Intercept 0.3381 0.4029
Physical functioning 0.0035* 0.0039*
Role functioning 0.0007 0.0008†
Emotional functioning 0.0011† 0.0015‡
Cognitive functioning 0.0007
Social functioning 0.0007 0.0007
Global health status/QoL 0.0009
Fatigue 0.0003
Nausea and vomiting 0.0002
Pain 0.0021* 0.0021*
Dyspnoea 0.0001
Insomnia 0.0001
Appetite loss 0.0001
Constipation 0.0005
Diarrhea 0.0004
Financial difficulties 0.0001
* p  0.001; † p  0; ‡ p  0.01.
QoL, quality of life.
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To the best of our knowledge, this is the first study in
NSCLC that derives utility scores from EORTC QLQ-C30
data using the EQ-5D in patients. In patients with metastatic
prostate cancer, a study mapping FACT-P and EORTC QLQ-
C30 to EQ-5D utility scores obtained a R2 value of 0.582 for
its best model, meaning that it explained 58.2% of the
observed variation in the validation sample.13 Other articles
that map EORTC QLQ-C30 to utilities using the EQ-5D have
been recently published with comparable outcomes in
breast,14 gastric,15 and esophageal cancers.16 Our best model
was developed through stepwise variable reduction to ensure
a balance between model complexity and goodness-of-fit.
Additional variables in the full model may overfit the data,
compared with the reduced model. A small improvement in
goodness-of-fit, assessed by R2, was observed with our re-
duced model (0.58) in contrast to the full model (0.57).
Limitations of this study include a relatively small
sample size and the lack of a unique population set to test for
external validity. The population tariffs were also based on a
subset of the general US population, which may not appro-
priately represent health preference in Canadian patients with
NSCLC. The mean EQ-5D utility (0.76  0.20) was surpris-
ingly high, given that half of the patients had stage IV
disease, and little variability was found across different dis-
ease states. The high utility score may reflect a biased sample
of higher performance status patients who were willing to
complete the questionnaires. However, similar scores to ours
were obtained in one of the few studies to calculate EQ-5D
utility scores in patients with lung cancer, in which the mean
utility score was 0.74  0.15 using the same US tariffs in
patients with stage III or IV disease.17 Using UK tariffs, the
mean utility score was 0.67  0.22. In that study, utility
scores decreased with worsening performance status. How-
ever, in our study, we did not collect data on performance
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FIGURE 2. Scatter plot of actual versus
predicted utility scores with corresponding
histogram. The vertical distance between
the point and the diagonal line represents
the error between actual and predicted util-
ity scores.
TABLE 4. Actual and Predicted Utility Scores, by Subgroup
Actual Utility
Score
Predicted, Linear
Model
Whole sample 0.76  0.20 0.76  0.15
Range 0.05–1.00 0.20–0.97
Disease stage
Stage I (n  34) 0.80  0.18 0.80  0.14
Stage II (n  16) 0.78  0.23 0.80  0.12
Stage III (n  36) 0.73  0.23 0.74  0.13
Stage IV (n  86) 0.75  0.15 0.77  0.13
Relapse free
Chemotherapy (n  9) 0.76  0.04 0.74  0.06
Post chemotherapy (n  27) 0.76  0.21 0.76  0.12
No chemotherapy (n  34) 0.77  0.22 0.80  0.16
Relapse
Chemotherapy (n  24) 0.69  0.25 0.72  0.18
Erlotinib (n  31) 0.77  0.17 0.73  0.16
No current treatment (n  33) 0.75  0.20 0.75  0.16
Locally advanced
Chemotherapy (n  14) 0.78  0.17 0.77  0.14
Jang et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1956
status, and subgroup analysis by disease status may not have
as large an impact on utility scores as performance status.
Finally, few patients enrolled in the study had reported
low utility scores (e.g., 0.4). This may be reflected in the
poorer performance of the models for patients who had low
utility scores.
CONCLUSION
This study demonstrates the feasibility of converting
QoL data into utilities in patients with NSCLC using linear
modeling. If the predictive QLQ-C30 variables found in our
study is validated in an independent series of patients, then
EORTC QLQ-C30 data could be used to derive utility scores
in patients with NSCLC. This may, in turn, further the ability
to estimate cost utility of therapies for economic evaluations
when utility values are not collected during the clinical trial.
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